Neurological disorder could be reason why you're 'tired all the time'
A GP has said that people experiencing certain symptoms might want to consider asking their doctors about a specific condition
If you're constantly feeling run down and under the weather, it might be worth seeing if a certain health condition could be the culprit. However, according to one doctor, it might not be so straightforward to diagnose.
Dr Asif Ahmed, an England-based GP, suggested that those grappling with certain common symptoms might want to discuss the possibility of Functional Neurological Disorder (FND) with their doctors. He said: "We don't fully know why or how it happens, but [experts] think that there's a problem with the signal between the brain and the rest of the body."
He explained that the problem is not just how your brain receives signals from the rest of the body - but how it sends signals out too. Dr Ahmed noted that this condition typically doesn't cause "any structural damage to the nerves of the brain.", reports Surrey Live.
The NHS Inform website states that the issues occur "on a level of the brain that you cannot control". Symptoms of FND can vary greatly from person to person. According to Dr Ahmed, the warning signs can be "so varied and widespread".
NHS Inform highlights key symptoms to watch out for:
Limb weakness
Functional/dissociative seizures
Tremors
Gait disorder (problems walking, such as dragging leg, feeling unsteady or making excessive movements)
Facial or muscle spasm
Functional tics
Drop attacks (falling to the ground suddenly without losing consciousness)
Speech and swallowing difficulties
Persistent postural perceptual dizziness (gets worse while walking or in crowded spaces)
Vision problems (vision can become blurred or reduced, you could start seeing double, or develop light sensitivity)
Chronic pain, persistent fatigue, and sleep issues are also flagged as potential indicators of this condition. It could also lead to mental health issues such as anxiety, depression, and PTSD.
Dr Ahmed highlighted that pinpointing Functional Neurological Disorder (FND) as the root of your health troubles can be a drawn-out and complex process. The diagnosis often relies on a method of eliminating other likely causes one-by-one as there isn't yet a single definitive test to identify the condition.
The diagnostic journey can sometimes uncover additional health issues FND patients might be facing. This could involve conducting specific blood tests and scans to fully investigate any concerns.
According to the NHS, the causes of "FND can happen for a wide range of reasons" and differ significantly from one individual to another. Moreover, having an existing neurological condition may heighten the risk of developing FND.
While there currently is no absolute cure for FND, a variety of rehabilitation therapies are available. These aim to 'retrain the brain,' assisting patients in improving their ability to perform daily tasks.
Medications may also be beneficial in addressing certain symptoms associated with FND, such as pain, depression, and anxiety. It's best to consult with a healthcare provider in determining whether medication is a suitable option for managing FND.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Leader Live
14 minutes ago
- Leader Live
Mass rollout of weight loss jabs begins on NHS
Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years. The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems. Patients previously needed to access the drugs through a special weight loss service. But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout. And pharmacy experts also said there could be pressure on supplies of the drug. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow. GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack. Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪 🔗Learn more: — EU Medicines Agency (@EMA_News) January 4, 2025 She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. 'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'. She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.' Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately. 'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly. 'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. 'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. 'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. 'The biggest concern we have is that prescribing these medications alone misses the point. 'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. 'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.' Around 29% of the adult population in the UK is obese. Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity. 'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay. 'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'
Leader Live
15 minutes ago
- Leader Live
Mounjaro weight loss jab: All you need to know
Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.
South Wales Guardian
17 minutes ago
- South Wales Guardian
Mounjaro weight loss jab: All you need to know
Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.
